The Future Of The Clinical Trial Imaging Market Trends And Opportunities To 2030

Clinical Trial Imaging Industry Overview

The global clinical trial imaging market size was estimated at USD 1.14 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.60% from 2024 to 2030. The market growth is anticipated to be fueled by the growing biotechnology and pharmaceutical sectors, coupled with rising investments in research and development for the creation of new drugs aimed at treating various diseases. Medical imaging plays a pivotal role in advancing the development of innovative life science products.

Gather more insights about the market drivers, restrains and growth of the Clinical Trial Imaging Market

Despite the ever-changing nature of the medical imaging industry, the biotechnology and pharmaceutical industries are showing sustained growth. This is primarily due to the increased investment in medical imaging companies, as well as the occurrence of mergers and acquisitions that involve the incorporation of cutting-edge imaging technologies to facilitate clinical trials for medical devices.

Advancements in technology are bringing substantial improvements to the collection, evaluation, and submission of clinical trial imaging data. Technology-enabled imaging, especially image analysis software, provides various benefits to clinical studies, such as consistency, data accuracy, adaptability, and compliance. For instance, image analysis software is used to direct and manage a reader by analyzing imaging time points. In addition, the increased use of imaging technology, along with the enhanced power of computing, is expected to drive the usage of imaging in clinical trials. The Quantitative Imaging Biomarkers Alliance (QIBA) protocol has come up with standardized methods and imaging procedures with uniform procedures to be implemented for attaining statistical and precise endpoints in clinical trials.

The Covid-19 pandemic has adversely impacted the healthcare system in most countries, leading to a disruption in medical studies, and research activities, and reduced sponsorship for research involving clinical trials. The pandemic hampered the clinical trial timeline as numerous ongoing studies were delayed and planned studies were cancelled. Unfavorable changes in regulations and guidelines, supply chain disruption, recruitment challenges for clinical trials, fear of viral spread, and shutting down of most manufacturers during lockdown have adversely impacted the market. However, introducing virtual imaging trials during the COVID-19 pandemic is expected to open new avenues for adopting these devices. The development of advanced computational models helps better assess CT and radiography images, which are expected to help in the early diagnosis of COVID-19 patients. The market has witnessed a bounce back by 2022 Q2 due to increased R&D activities and improvement in supply and distribution channels.

Many patents have been filed in the realm of enhancing image evaluation and capturing. In addition, imaging core lab provider’s offer patented technologies that are anticipated to assist pharmaceutical companies in reducing their development timelines. As an example, IXICO provides a diagnostic tool called Assessa, which enhances decision-making in clinical trials for conditions related to memory, including schizophrenia, Parkinson's, and Alzheimer's disease, as well as neurological disorders such as dementia and cognitive impairment.However, the high cost of machinery and their installation, and the enormous cost of clinical trials may limit the market growth during the forecast periods. Advancements in technology are bringing substantial improvements to the collection, evaluation, and submit clinical trial imaging data. Technology-enabled imaging especially image analysis software provides various benefits to clinical studies such as consistency, data accuracy, adaptability as well as compliance. For instance, image analysis software is used to direct and manage a reader via analysis of imaging time points.

Order a free sample PDF of the Clinical Trial Imaging Market Intelligence Study, published by Grand View Research.

Key Companies profiled:

• IXICO plc

• Navitas Life Sciences

• Resonance Health

• ProScan Imaging

• Radiant Sage LLC

• Medpace

• Biomedical Systems Corp

• Cardiovascular Imaging Technologies

• Intrinsic Imaging

• BioTelemetry

Recent Developments

• In March 2023, Clario launched a cloud-based image viewer specifically for clinical trials. This innovation aims to streamline medical image analysis and improve its accessibility within the clinical research context

• In May 2023, Cleerly has partnered with ProScan Imaging to provide personalized solutions for cardiac health, which involve analyzing and devising treatment strategies for cardiovascular issues. The partnership is expected to leverage Cleerly's AI-powered platform to examine coronary CT angiography (CCTA) images